PDAC remains one of the most daunting challenges in oncology, accounting for over 90 percent of pancreatic cancer cases globally, with a dismal five-year survival rate under five percent for metastatic disease. Current treatment modalities offer limited success; surgical resection is viable for only a fraction of patients with localized disease, while systemic chemotherapy and radiation yield modest benefits and are often accompanied by severe side effects. The pressing need for more effective and precise therapeutic strategies has driven the exploration of molecular targets unique to PDAC cells, with CD44v6 emerging as an especially promising candidate due to its selective tumor-associated expression.

The team led by Professor Marika Nestor at Uppsala University embarked on a multifaceted investigation evaluating the therapeutic potential of [177Lu]Lu-AKIR001, a radioligand labeled with lutetium-177 (^177Lu), a beta-emitting radionuclide known for its utility in targeted cancer treatments. Fundamentally, this agent harnesses the specificity of antibody-based targeting to deliver cytotoxic radiation directly to CD44v6-expressing tumor cells, sparing healthy tissue and reducing systemic toxicity. Initial in vitro analyses confirmed the expression of CD44v6 in three of four tested PDAC cell lines, validating the relevance of this molecular target for heterogeneous pancreatic tumors.

Subsequent in vivo experiments employed murine xenograft models bearing human PDAC tumors, offering a critical platform to evaluate the biodistribution, tumor uptake, and therapeutic efficacy of [177Lu]Lu-AKIR001. Remarkably, the radiopharmaceutical exhibited robust and selective tumor accumulation, as evidenced by quantitative biodistribution studies and corroborated by sophisticated SPECT/CT imaging performed 96 hours post-injection. This selective uptake underscores the precision of the treatment modality, which is fundamental to its therapeutic promise.

Therapeutic interventions administered in these preclinical trials varied in dose and combination with conventional chemotherapy agents to explore synergy and optimize efficacy. Notably, a single administration of 12 megabecquerels (MBq) of [177Lu]Lu-AKIR001 alone resulted in complete tumor regression in 40 percent of cases, while a lower dose of 4 MBq combined with paclitaxel chemotherapy achieved remission in 14 percent of the treated population. These findings delineate an activity-dependent response and provide crucial data for designing dosing regimens in future clinical trials.

A pivotal aspect of the study involved detailed toxicity monitoring to assess the safety profile of [177Lu]Lu-AKIR001. Encouragingly, no significant adverse effects were noted in treated animals, indicating a favorable therapeutic window. This outcome holds immense significance, as systemic toxicities limit the applicability of many radiopharmaceutical and chemotherapeutic agents. The minimized off-target effects arise from the targeted nature of the therapy, which concentrates radioactivity within tumor sites harboring CD44v6 expression.

The advent of targeted radiotherapies has revolutionized treatment paradigms for several malignancies, notably prostate cancer and neuroendocrine tumors. The success of [177Lu]Lu-AKIR001 in preclinical PDAC models expands this therapeutic frontier to a cancer type historically refractory to conventional treatment. Professor Nestor emphasizes the urgent need for new modalities in PDAC management and positions CD44v6-targeted radioligand therapy as a viable candidate to transform clinical outcomes for patients devastated by this malignancy.

Moreover, this work integrates seamlessly within a broader clinical research framework where [177Lu]Lu-AKIR001 is already under evaluation for other cancers in ongoing clinical trials. The expansion of patient inclusion criteria in these programs reflects growing confidence in the agent’s utility and safety, and this preclinical evidence in PDAC provides a compelling rationale for initiating human studies specifically targeting this disease.

The molecular specificity and versatility inherent to [177Lu]Lu-AKIR001 enable it to be potentially combined with existing chemotherapy protocols, enhancing therapeutic potency without exacerbating toxicities. This combinatorial approach may harness synergistic mechanisms that disrupt cancer cell survival pathways more effectively than monotherapies, addressing the heterogeneity and adaptive resistance typical of PDAC. The research team has meticulously mapped the sensitivity profiles of various chemotherapeutic agents against PDAC cell lines, informing personalized treatment designs that optimize combination efficacy.

From a mechanistic perspective, [177Lu]Lu-AKIR001 operates by delivering localized beta radiation, inducing double-stranded DNA breaks within targeted tumor cells, thereby triggering apoptosis and inhibiting proliferation. The therapeutic index of such radioimmunotherapy depends critically on receptor expression density, radioligand affinity, and radionuclide characteristics. This study’s comprehensive biodistribution and binding assays underscore the high affinity and specific delivery capacity of the radiopharmaceutical, crucial parameters for clinical translation.

The high-resolution SPECT/CT imaging employed in this study not only corroborates biodistribution data but also offers valuable insights into in vivo tumor targeting dynamics over time. Visualization at 96 hours post-injection reveals pronounced tumor uptake with minimal accumulation in non-target organs, underscoring the precision of the therapeutic mechanism and allowing for non-invasive assessment of treatment response in live subjects.

Taken collectively, the data present a compelling preclinical proof of concept for [177Lu]Lu-AKIR001 as an effective and safe therapeutic agent against CD44v6-positive PDAC, with significant implications for future clinical practice. This research bridges a critical gap in PDAC treatment, offering a tailored approach that exploits unique tumor biology while preserving patient quality of life through reduced systemic toxicity.

As the clinical investigation of targeted radiotherapies continues to expand, the successful application in PDAC models sets the stage for translational efforts geared towards human trials. The promising preclinical results demonstrated by Professor Nestor and colleagues invigorate the field with a novel therapeutic strategy poised to counteract one of the deadliest cancers, reflecting a pivotal milestone in precision oncology.

Subject of Research: Pancreatic ductal adenocarcinoma (PDAC) treatment using targeted radiopharmaceutical therapy.

Article Title: Open Access [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies

News Publication Date: May 13, 2026

Web References:
https://jnm.snmjournals.org/content/early/2026/04/22/jnumed.125.271705
http://dx.doi.org/10.2967/jnumed.125.271705

References:
Gustafsson, A., Svedberg, H., Rinne, S. S., Nestor, M., Bertilsson, F., Lindskog, C., Selvaraju, R. K., & Lundgren Mortensen, A. C. (2026). [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. Journal of Nuclear Medicine.

Image Credits: Amanda Gustafsson (Department of Immunology, Genetics and Pathology, Uppsala University; Science for Life Laboratory, Uppsala University); Anja Mortensen (Department of Immunology, Genetics and Pathology, Uppsala University; Science for Life Laboratory, Uppsala University; Department of Molecular Medicine and Surgery, Karolinska Institutet); Ram Kumar Selvaraju (Department of Medicinal Chemistry, Uppsala University)

Keywords: Targeted radiotherapy, pancreatic ductal adenocarcinoma, CD44v6, [177Lu]Lu-AKIR001, radiopharmaceutical therapy, precision oncology, beta-emitting radionuclide, SPECT/CT imaging, xenograft models, chemotherapy combination, tumor targeting, personalized medicine

NP137 operates through the blockade of netrin1, a molecule intricately linked with cellular processes that cancer cells exploit to evade chemotherapy. By inhibiting netrin1, NP137 fundamentally alters the tumor microenvironment, making cancer cells more susceptible to conventional chemotherapy regimens. This strategy diverges from traditional approaches that solely aim at directly killing tumor cells, positioning NP137 as a pioneering agent that sensitizes tumors via molecular modulation.

The combinatorial regimen of NP137 with mFOLFIRINOX—a chemotherapy protocol comprised of folinic acid, fluorouracil, irinotecan, and oxaliplatin—has demonstrated encouraging safety profiles and clinical activity in early-phase trials involving patients with locally advanced PDAC. Mechanistic insights derived from extensive translational analyses underscore the uniqueness of NP137’s mode of action. These findings prompt a reevaluation of netrin1’s role in tumorigenesis and resistance, suggesting it as a promising therapeutic target.

Central to this innovation is the concept of epithelial-to-mesenchymal transition (EMT), a biological process where cancer cells acquire migratory and invasive characteristics that propagate metastatic spread and therapeutic resistance. The Lap-NET1 clinical study has specifically focused on patients with locally advanced PDAC under the premise that EMT drives the metastatic cascade. By intervening in this process via netrin1 blockade, NP137 may inhibit a fundamental mechanism fueling pancreatic tumor aggressiveness.

The significance of EMT extends beyond localized tumors, as evidence suggests its activity persists within metastatic lesions. This insight provokes the hypothesis that patients afflicted with metastatic PDAC could also benefit from NP137 combined with chemotherapy, potentially broadening the therapeutic window for patients previously deemed refractory to available treatments. Such an approach signals a paradigm shift in the management of advanced pancreatic cancer.

The next milestone for NP137 is its evaluation in a randomized phase 2 trial that will investigate its integration with the current standard of care for first-line treatment in metastatic PDAC patients. This trial is designed not only to verify efficacy and safety but also to critically explore the predictive capability of a neogenin immunohistochemistry (IHC) test. The neogenin marker may serve as a biomarker to identify patients who stand to gain the most therapeutic benefit from NP137—the epitome of precision medicine.

While the initial clinical outcomes are optimistic, the journey toward integrating NP137 into standard clinical practice depends on robust validation. The randomized phase 2 study will provide pivotal data to determine whether NP137’s addition extends overall survival, improves quality of life, and possibly delays or prevents disease progression. Success here could herald a novel therapeutic avenue for PDAC, where historically survival rates have remained dismal despite numerous trials.

Further translational research reveals that netrin1’s blockade does not merely ‘disable’ the tumor cells but dynamically remodels the tumor microenvironment, potentially impairing the supportive stroma that often shelters cancer cells from cytotoxic agents. By reprogramming this hostile niche, NP137 may enhance drug delivery and efficacy, illustrating the multifaceted impact of this therapeutic strategy.

Notably, the safety profile emerging from the initial studies highlights a tolerable adverse event spectrum, an essential consideration given the often debilitating side effects associated with combination chemotherapy. By minimizing additive toxicity, NP137 positions itself as an adjunct therapy that could be feasibly incorporated into existing treatment protocols without compromising patient safety.

The discovery and development of NP137 align with the growing movement toward biomarker-driven oncology, where treatments are tailored based on individual molecular landscapes. Utilizing neogenin IHC tests to select patients exemplifies this tailored approach, optimizing therapeutic response while sparing non-responders from unnecessary treatment burdens.

This scientific advancement also reinvigorates the broader endeavor to unravel the mechanistic underpinnings of chemotherapy resistance—a phenomenon that transcends pancreatic cancer and impacts many malignancies. Understanding how netrin1 signaling intertwines with EMT and cellular resilience opens avenues for potentially applicable cross-cancer therapies.

Beyond the immediate clinical implications, the introduction of NP137 raises compelling questions for future research. Could netrin1 blockade synergize with emerging immunotherapies? Might combining NP137 with other targeted agents amplify therapeutic benefits? The unfolding narrative presents fertile ground for subsequent investigations that could reshape oncologic treatment landscapes.

Ultimately, the trajectory of NP137—from conceptualization to clinical validation—epitomizes the convergence of molecular biology, translational research, and patient-centric clinical trials. Its promise in dismantling the biochemical fortress of chemotherapy resistance offers hope against one of the deadliest cancers, demanding attention and optimism from the global scientific and medical communities.

As the randomized trials advance, the oncology field watches eagerly to see whether NP137 will fulfill its transformative potential, delivering a much-needed breakthrough in pancreatic cancer therapeutics. For patients and clinicians alike, the hope kindled by this study is a beacon of progress in the relentless battle against cancer.

Subject of Research: Netrin1 blockade in pancreatic ductal adenocarcinoma (PDAC) and its impact on chemotherapy resistance

Article Title: Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer

Article References:
Roth, G., Artru, P., Bouche, O. et al. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10436-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10436-4